Evidence map›Paper›PMID 36253738›Full record

ArticleBMC endocrine disorders2022

Prevalence, awareness, treatment, and control of type 2 diabetes mellitus among the adult residents of tehran: Tehran Cohort Study.

Alireza Oraii, Akbar Shafiee, Arash Jalali, Farshid Alaeddini, Soheil Saadat, Farzad Masoudkabir, Ali Vasheghani-Farahani, Amirhossein Heidari, Saeed Sadeghian, Mohamamdali Boroumand and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC endocrine disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. The Protective Effects ofCurrent medicinal chemistry · 2026
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Alireza Oraii *Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-2422-2930
Akbar Shafiee *Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0001-6912-7788
Arash JalaliTehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. arjalali@tums.ac.ir.ORCID http://orcid.org/0000-0003-3225-8498
Farshid AlaeddiniTehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-2676-547X
Soheil SaadatDepartment of Emergency Medicine, University of California, Irvine, California, USA.ORCID http://orcid.org/0000-0002-2744-7983
Farzad MasoudkabirTehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0001-8098-7121
Ali Vasheghani-FarahaniTehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0003-3346-2124
Amirhossein HeidariCardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0003-4327-8814
Saeed SadeghianTehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-9577-3780
Mohamamdali BoroumandTehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0003-1016-4757
Abbasali KarimiTehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-8162-9905
Oscar H FrancoInstitute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0002-4606-4929
Tehran University of Medical Sciences · IRIslamic Azad University Medical Branch of Tehran · IRUniversity of Bern · CHUniversity of California, Irvine · US

Funding

Ministry of Health and Medical Education 1296006-1603003000
6 · The paper itself

Abstract

backgroundThe prevalence of type 2 diabetes mellitus has increased in the past decades. We investigated the prevalence of diabetes and its awareness, treatment, and control among adult residents of Tehran.

methodsWe used the recruitment phase data of the Tehran Cohort study, enrolling a random sample of adult residents of Tehran aged ≥35 years. Diabetes was defined as self-report, current use of glucose-lowering medications, and/or fasting plasma glucose (FPG) ≥126mg/dl. Impaired fasting glucose (IFG) was defined as an FPG of 100-125mg/dl. Awareness was defined as diabetes self-report, treatment as receiving glucose-lowering medications, and glycemic control as FPG <126mg/dl. The age- and sex-weighted estimates were calculated using the 2016 national census. Logistic regression models were used to determine the factors associated with diabetes awareness, treatment, and control.

resultsA total of 8151 participants were included. Age- and sex-weighted prevalence of diabetes mellitus and IFG were 16.7% (95% CI: 15.1-18.4) and 25.1% (95% CI: 23.1-27.1), respectively. Diabetes was more prevalent in the eastern and central districts of Tehran. Advanced age (OR per 1-year increase: 1.026, 95% CI: 1.021-1.030), male sex (OR: 1.716, 95% CI: 1.543-1.909), higher BMI levels (OR for BMI ≥35 vs. <20 kg/m

conclusionThere is a high prevalence of diabetes and IFG among adult residents of Tehran. Additionally, more than two-thirds of treated diabetics living in Tehran remain uncontrolled.

Indexed as

Diabetes MellitusDiabetes Mellitus, Type 2HypertensionPrediabetic StateAdultBlood GlucoseCohort StudiesFastingFemaleGlucoseHumansIranMalePrevalenceBlood GlucoseGlucoseAwarenessControlDiabetes mellitusEpidemiologyPrevalenceTreatment

Identifiers

PMID36253738
PMCPMC9578278
OpenAlexW4306407868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.